← Back to Calendar

Rocket Pharma Q4 2025 Earnings

Rocket Pharma · $RCKT
Standard Review Earnings
Catalyst Date
March 5, 2026
Date Status
39d ago (past)
Review Type
Standard (10 mo)

Live Company Data NGM

Updated just now · Data: FMP
Current Price
$3.49 -29.35%
$-1.45 today
Day: $3.48 – $3.64
Market Cap
N/A
Shares out: 109.12M
Float: 87.08M
52-Week Range
$2.19
$8.26
Current price is at 21% of 52-week range
Avg Volume
3.41M
Beta
0.57
vs. S&P 500
Sector
Healthcare
Biotechnology
⚠️ Financial data is for informational purposes only. Not investment advice. Prices may be delayed.
Track $RCKT catalysts → get weekly FDA alerts Subscribe Free on Substack →

Indication

Q4 2025 earnings + KRESLADI PDUFA preparation update

Key Notes

Q4 2025 earnings reported ~March 2026. Key catalyst: KRESLADI BLA PDUFA March 28, 2026 for LAD-I gene therapy — would be company's first approved product.
⚠️ Not Investment Advice: This information is provided for educational purposes only. PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period, issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on historical base rates and do not account for drug-specific factors. Always consult a financial advisor before making investment decisions.

Discussion

Share your analysis, research, or questions about this catalyst. No account required.

Rate limit: 5/hr per email
Loading comments...
← Back to Full Calendar